^
Association details:
| Biomarker: | CXCL9 elevation |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarker results and preclinical rationale for combination lenvatinib and pembrolizumab in advanced endometrial carcinoma.
Published date:
05/16/2018
Excerpt:
We report biomarker analyses from a phase 1b/2 trial in advanced endometrial cancer (EC) and preclinical rationale for the activity of combination LEN + PEM….significant associations were found between increases in CXCL9 and CXCL10 levels and patients with compete, partial, or unconfirmed partial responses (all P< 0.05).
DOI:
10.1200/JCO.2018.36.15_suppl.5597
Trial ID:
